**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
X: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © European Alliance of Associations for Rheumatology, EULAR 2024. Published by BMJ. All rights reserved.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 1403** Referral of patients with suspected polymyalgia rheumatica: how complete is our view of 'planet PMR'?
D Camellino, E L Matteson

Views on news

- 1406** HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis
J Braun, E Märker-Hermann, M Rudwaleit, J Sieper

Reviews

- 1409** B-cell depletion in autoimmune diseases
G Schett, G Nagy, G Krönke, D Mielenz
- 1421** From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here?
D J Clauw

Criteria

- 1428** 2023 EULAR classification criteria for hand osteoarthritis
I K Haugen, D T Felson, A Abhishek, F Berenbaum, S Bierma-Zeinstra, K S Dziedzic, J J Edwards, M Englund, M Hermann-Erikson, G Herrero-Beaumont, C Hill, M L Ishimori, H Jonsson, T Karjalainen, Y Y Leung, E Maheu, C D Mallen, M Marshall, R H Moe, R Ramonda, V Ritschl, M JPF Ritt, T A Stamm, Z Szekanecz, F van der Giesen, L A van de Stadt, C van der Meulen, R Wittoek, E Greibrokk, H Laheij, M Kloppenburg

Recommendations

- 1436** Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group
K K Keller, C B Mukhtyar, A W Nielsen, A K Hemmig, S L Mackie, S E Sattui, E-M Hauge, A Dua, T Helliwell, L Neill, D Blockmans, V Devauchelle-Pensec, E Hayes, A J Venneboer, S Monti, C Ponte, E De Miguel, M Matza, K J Warrington, K Byram, K Yaseen, C Peoples, M Putman, L Lally, M Finikiotis, S Appenzeller, U Caramori, C E Toro-Gutiérrez, E Backhouse, M C G Oviedo, V R Pimentel-Quiroz, H I Keen, C E Owen, T Daikeler, A de Thurah, W A Schmidt, E Brouwer, C Dejaco

- 1443** EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update
M de Wit, K Aouad, M Elhai, D Benavent, H Bertheussen, S Blackburn, P Böhm, C Duarte, M Falahee, S Karlfeldt, U Kiltz, E F Mateus, D P Richards, J Rodríguez-Carrio, J Sagen, R Shummalieva, S R Stones, S W Tas, W Tillett, A Vieira, T-C Wilhelmer, C Zabalán, J Primdahl, P Studenic, L Gossec

Rheumatoid arthritis

- 1454** Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
E Feist, R M Fleischmann, S Fatenejad, D Bukhanova, S Grishin, S Kuzkina, M Luggen, E Nasonov, M Samsonov, J S Smolen

Inflammatory arthritis

- 1465** Itaconate is a metabolic regulator of bone formation in homeostasis and arthritis
M Kieler, L S Prammer, G Heller, M Hofmann, S Sperger, D Hanetseder, B Niederreiter, A Komljenovic, K Klavins, T Köcher, J S Brunner, I Stanic, L Oberbichler, A Korosec, A Vogel, M Kerndl, D Hromadová, L Musiejovsky, A Hajto, A Dobrijevic, T Piwonka, A Haschemi, A Miller, P Georgel, D Marolt Presen, J Grillari, S Hayer, J-P Auger, G Krönke, O Sharif, D Aleitaha, G Schabbauer, S Blüml

Psoriatic arthritis

- 1480** Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
L Gossec, L C Coates, D D Gladman, J A Aelion, J Vasandani, A Pinter, J F Merola, A Kavanaugh, J Reddy, R Wang, M Brunori, Y Klyachkin, C Deignan, P J Mease

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008


This journal is a member of and subscribes to the principles of the Committee on Publication Ethics


<http://publicationethics.org/>



When you have finished with this please recycle it

Systemic lupus erythematosus


1489 Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
 OPEN ACCESS
M Kostopoulou, C B Mukhtyar, G Bertias, D T Boumpas, A Fanouriakis


1502 Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
 OPEN ACCESS
C Aranow, C F Allaart, Z Amoura, I N Bruce, P C Cagnoli, W W Chatham, K L Clark, R Furie, J Groark, M B Urowitz, R van Vollenhoven, M Daniels, N L Fox, Y I Grogan, R B Henderson, A van Maurik, J C Ocran-Appiah, M Oldham, D A Roth, D Shanahan, P P Tak, Y O Teng

Systemic sclerosis

1513 Racial variability in immune responses only partially explains differential systemic sclerosis disease severity
K E Kuchinad, J S Kim, A Woods, G Leatherman, L Gutierrez-Alamillo, M D Mayes, R Domsic, P S Ramos, R M Silver, J Varga, L A Sakeetkoo, S Kafaja, V K Shanmugan, J Gordon, L Chung, E J Bernstein, P Gourh, F Boin, D L Kastner, S L Zeger, L Casciola-Rosen, F M Wigley, A A Shah

Vasculitis

1522 Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis
 OPEN ACCESS
C Fang, L Du, S Gao, Y Chen, Z Chen, Z Wu, L Li, J Li, X Zeng, M Li, Y Li, X Tian

1536 Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis
 OPEN ACCESS
J Thiel, F M Schmidt, R Lorenzetti, A Troilo, I Janowska, L Nießen, S Pfeiffer, J Staniak, B Benassini, M-T Bott, J Korzhenevich, L Konstantinidis, F Burghbacher, A-K Dufner, N Frede, R E Voll, J Stuchly, M Bakardjieva, T Kalina, C R Smulski, N Venhoff, M Rizzi

Myositis

1549 Pathological autoantibody internalisation in myositis
 EDITOR'S CHOICE
I Pinal-Fernandez, S Muñoz-Braceras, M Casal-Dominguez, K Pak, J Torres-Ruiz, J Musai, S Dell'Orso, F Naz, S Islam, G Gutierrez-Cruz, M D Cano, A Matas-Garcia, J Padrosa, E Tobias-Baraja, G Garrabou, I Aldecoa, G Espinosa, C P Simeon-Aznar, A Guillen-Del-Castillo, A Gil-Vila, E Trallero-Araguás, L Christopher-Stine, T E Lloyd, T Liewluck, E Naddaf, W Sienzel, S A Greenberg, J M Grau, A Selva-O'Callaghan, J C Milisenda, A L Mammen

Paediatric rheumatology

1561 Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
 OPEN ACCESS
H I Brunner, J D Akikusa, E Al-Abadi, J F Bohnsack, A L Boteanu, G Chedeville, R Cuttica, W De La Pena, L Jung, O Kasapcopur, K Kobusinska, G S Schuler, C Neiva, R Rivas-Chacon, J C Rizo Rodriguez, M Vazquez-Del Mercado, L Wagner-Weiner, J E Weiss, C Wouters, H Posner, A Wouters, C Chang, C White, K Kanik, S Liu, A Martini, D J Lovell, N Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

Osteoarthritis

1572 Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study)
 OPEN ACCESS
Y-M Pers, R Soler-Rich, G Vadalà, R Ferreira, C Duflos, M-C Picot, F Herman, S Broussous, A Sánchez, D Noriega, F Ardura, M Alberca Zaballós, V García, V Gordillo Cano, M González-Vallinas, V Denaro, F Russo, J Guicheux, J Vilanova, L Orozco, H-J Meisel, M Alfonso, F Rannou, Y Maugars, F Berenbaum, F P Barry, K Tarte, P Louis-Plence, G Ferreira-Dos-Santos, J García-Sancho, C Jorgensen, RESPINE consortium

Epidemiology

1584 Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
 OPEN ACCESS
B Fansogullari, S Lawson-Tovey, K L Hyrich, L Gossec, L Carmona, A Strangfeld, E F Mateus, M Schäfer, A Rodrigues, E Hachulla, J A Gomez-Puerta, M Mosca, P Durez, L Trefond, T Goulonok, M Cornalba, E Sienova, I Bulina, E Strakova, J Zepa, N Roux, O Brocq, E Veillard, B Raffener, G R Burmester, X Mariette, P M Machado, EULAR COVAX Registry

Images in rheumatology

1596 Paraspinal tophi
J Wu, Y Zhang

Letters

1597 Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
A Haghikia, T Hegelmaier, D Wolleschak, M Böttcher, V Pappa, J Motte, D Borie, R Gold, E Feist, G Schett, D Mouggiakakos

- 1598** Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block
A-L Stefanski, H Rincon-Arevalo, I Dressler-Steinbach, N Nomovi, A Mackert, A Aue, J Ritter, A Wiedemann, F Szelinski, E Schrezenmeier, A A Kühl, A C Lino, W Henrich, T Dörner
- 1600** Altered CD8⁺ T cell subpopulation in the bone marrow microenvironment of cynomolgus monkeys with spontaneous ankylosing spondylitis
T Guan, Z Bian, H Gao, Y He, J Yuan, H Wan, S Tang, Y Li, J Qiu, P Luo, X Ye, S Liang, S Chen, N Cai, Y Guan, J Liu, Z Zhao, H Jia, W Yang, W Li
-
- Electronic pages**
- e22** Correspondence on 'Current myositis clinical trials and tribulations' by Saygin *et al*
S F Azevedo, A Valenzuela, C A Benitez, D A Isenberg, E Naddaf, H Chinoy, J Vencovský, L Gupta, L McCann, M Kuwana, M M Dimachkie, S Sheno, L A Saketkoo, P M Machado
- e23** Response to: Correspondence on 'Current myositis clinical trials and tribulations' by Saygin *et al*
D Saygin, V Werth, J J Paik, J K Park, M Needham, I E Lundberg, L Christopher-Stine
- e24** Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis *et al*
J E Roberts, N Balmuri, J C Chang, J Cooper, O Harry, R Hetrick, J Jarvis, A M Knight, L B Lewandowski, T B Rubinstein, R Sadun, W D Soulsby, S Wenderfer, J M P Woo
- e25** Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis *et al*
A Fanouriakis, G Bertias, D T Boumpas
- e26** Correspondence on 'Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis' by Kim *et al*
R B M Landewé, M Boers
- e27** Correction: *Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy*